Skills Shortages could Scupper Singapores Growth Prospects
As increasing numbers of pharmaceutical companies expand into Singapore, and businesses experience high levels of staff movement as a result of heightened confidence amongst jobseekers, future growth could be affected by a marked skills shortage. That’s according to the latest Global Sentiment Survey from Berkley Group, which analyses employment and market perceptions internationally.
People Crisis Looms for Pharma Companies
Recent reports from the Ministry of Trade reveal that the Singapore economy grew 5.4% in Q1 2014 which has, in turn, led to increased investment in the region and heightened confidence amongst jobseekers and employers alike. Despite this, however, Berkley’s research reveals that future growth may be halted by a lack of available talent. The report revealed that 80% of the current workforce intends to move jobs in the next year, with 60% planning to do so within 6 months. This is in keeping with recent research from Sylvia Vorhauser-Smith, Senior Vice President of Research at PageUp People, which reveals that regular job hopping is prevalent in the country’s workforce.
Robust Attraction and Retention Strategy a must for Employers
This high level of predicted movement amongst the workforce is likely to exacerbate the already present concerns surrounding talent retention and attraction in Singapore. This, coupled with increasing pressure mounted on employers to hire locals before expats, means that staffing strategies need to be far more succinct to help organisations attract and retain those professionals with the requisite skill sets to prevent a slowdown in growth. This is a sentiment mirrored in Berkley’s research which reveals that, whilst 90% of those surveyed expect a pay rise in the coming year, very few reported financial incentives as a contributing factor in moving jobs (30%). In comparison, 57% acknowledged that career progression would be the biggest driver. These results suggest there is currently a significant disconnect between staff preferences and workplace incentives.
Wendy Cheong, Practice Director at Berkley Group, comments: “The Singapore economy is currently experiencing a period of intense change as plans for economic development and growth remains a high priority for the government. However, for businesses to remain competitive, it’s vital that they have the right talent on board, an objective that has long been a challenge with high levels of staff turnover and a heavy reliance on expats in the country. As recruitment activity looks set to increase, there will need to be a change in the mindset of employers to ensure they are providing the right opportunities to attract and retain staff to prevent marked skills shortages. As financial incentives continue to drop off the radar of the workforce, perhaps career development opportunities need to be considered as part of the talent attraction strategy.”
To see the report visit www.berkley.com.sg/research-download
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.